GTXI vs. MACK, RIGL, VSTM, RGLS, VNDA, XOMA, EBS, LXRX, ACRV, and TRVI
Should you be buying GTX stock or one of its competitors? The main competitors of GTX include Merrimack Pharmaceuticals (MACK), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Regulus Therapeutics (RGLS), Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), Acrivon Therapeutics (ACRV), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector.
Merrimack Pharmaceuticals (NASDAQ:MACK) and GTX (NASDAQ:GTXI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
GTX's return on equity of -6.24% beat Merrimack Pharmaceuticals' return on equity.
64.0% of Merrimack Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.5% of GTX shares are owned by institutional investors. 28.9% of Merrimack Pharmaceuticals shares are owned by insiders. Comparatively, 40.9% of GTX shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, GTX had 7 more articles in the media than Merrimack Pharmaceuticals. MarketBeat recorded 8 mentions for GTX and 1 mentions for Merrimack Pharmaceuticals. GTX's average media sentiment score of 0.00 equaled Merrimack Pharmaceuticals'average media sentiment score.
Merrimack Pharmaceuticals received 85 more outperform votes than GTX when rated by MarketBeat users. However, 73.60% of users gave GTX an outperform vote while only 67.00% of users gave Merrimack Pharmaceuticals an outperform vote.
Merrimack Pharmaceuticals is trading at a lower price-to-earnings ratio than GTX, indicating that it is currently the more affordable of the two stocks.
Merrimack Pharmaceuticals has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, GTX has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.
Summary
Merrimack Pharmaceuticals beats GTX on 6 of the 11 factors compared between the two stocks.
Get GTX News Delivered to You Automatically
Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GTXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
